GB2208149A - Pharmaceutical and cosmetic compositions based on pyridones and antibacterial agents - Google Patents

Pharmaceutical and cosmetic compositions based on pyridones and antibacterial agents Download PDF

Info

Publication number
GB2208149A
GB2208149A GB8816916A GB8816916A GB2208149A GB 2208149 A GB2208149 A GB 2208149A GB 8816916 A GB8816916 A GB 8816916A GB 8816916 A GB8816916 A GB 8816916A GB 2208149 A GB2208149 A GB 2208149A
Authority
GB
United Kingdom
Prior art keywords
composition according
carbon atoms
erythromycin
ppm
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB8816916A
Other versions
GB8816916D0 (en
GB2208149B (en
Inventor
Leger Didier Saint
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LOreal SA
Original Assignee
LOreal SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LOreal SA filed Critical LOreal SA
Publication of GB8816916D0 publication Critical patent/GB8816916D0/en
Publication of GB2208149A publication Critical patent/GB2208149A/en
Application granted granted Critical
Publication of GB2208149B publication Critical patent/GB2208149B/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/602—Glycosides, e.g. rutin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Description

1. t 1 1 Pharmaceutical and cosmetic compositions based on pyridones and
on antibacterial agents 2208149 The present invention relates to new compositions based on pyridone derivatives and on antibacterial agents of the macrolide and the pyranoside family, intended for use in treatments of dermatoses such as acne and in the 5 cosmetic treatment of the skin.
The aetiopathology of acne, although poorly defined, owes its origin to the formation of a characteristic lesion, the comedo. The latter results from the obstruca consequence of dyskerinfundibulum of the duct.
tion of the pilosebaceous duct as atinization of the region of the This obstruction has the major effect of modifying the rheological properties of the sebum, and the physiochemical properties of the medium. This modification leads to the hyperproliferation of the cutaneous resident strains, which trigger an inflammatory type reaction of the body.
Two types of Lesions are generally distinguished.
The first type corresponds to the so-called open comedo or blackhead, the clinical feature of which is commonplace and whose development remains limited. This type of comedo may be readily removed, either by extrusion, or by physical or chemical treatment by the use of topical agents known as keratolytics, which are well known per se.
The second type corresponds, initially, to the cleveLopment of the so-caLLed cLosed comeclones or microcysts, the finaL stage of which is the rupture of the piLosebaceous foLLicLe which has produced it and which reLeases into the clermis numerous infLammatory products in5 clucing reaction of the host body.
The Lesions which characterize infLammatory acne are hence intermediate stages of the microcysts, and are grouped together under the generic names of papuLes, pustuLes, noduLes or cysts, noduLocystic acne represent- ing the most severe form of acne.
At the present time the products which generate the infLammation, or the mechanisms by which they generate the infLammation, remain poorLy defined, aLthough many cLinicaL experiments suggest that the bacteriaL fLora, of which Propionibacterium acnes is the major representative, are strongLy impLicated.
It is known that the topicaL or systemic use of antibiotic compounds, such as erythromycin, cLinclamycin, Lincomycin or their derivatives, in the therapy of acne has as its immediate consequence a very obvious anti-infLammatory effect.
It is thought, moreover, that certain skin yeasts, in particuLar Pityrosporum ovaLe or Pityrosporum orbicuLare yeast, are present in the infLammatory acne Lesions, and it has been shown that Pityrosporum ovaLe was one of the primary causes of certain infLammatory skin conditions such as dandruff (pytiriasis capitis) and seborrheic 1 dermatitis.
During the rupture of the comedo, the Pityrosporum ovale yeast, or its transitory forms, are released and also generate inflammation.
The Applicant has discovered, and this forms the subject of the invention, that by combining pyridone deriv atives and antibacterial agents chosen from macrolide antibiotics and pyranosides, it was unexpectedly possible to improve the treatment of acne.
The Applicant has discovered that the combination of antifungal agents, of the pyridone derivative type, and antibacterial agents mentioned above combats the in flammation due to acne much more rapidly and more effec tively than an antifungal agent alone or an antibacterial agent alone.
The subject of the invention Is hence a pharma- ceutical composition intended for the treatment of acne, combining a pyridone derivative with certain antibacterial agents.
Another subject of the invention consists of the use of the composition defined above for the preparation of a composition for treating acne.
Other subjects of the invention will become apparent on reading the description and the examples which follow.
The composition intended for a topical application for the treatment of acne is essentially characterized in that it contains, in a physiologically acceptable medium, at least one pyridone derivative corresponding to the formula:
H < ']I--R 1 ( I) 4 2 3 in which:
R1 denotes a hydrogen atom, a linear or branched alkyl group having from 1 to 17 carbon atoms, a cycloalkyl group having from 5 to 8 carbon atoms, a cycloalkylalkylene group, the aLkylene group having from 1 to 4 carbon atoms, an aryl group, an aralkyl group, the alkyl group having from 1 to 4 carbon atoms, an arylalkenyl group, the alkenyl group having from 2 to 4 carbon atoms, it being possible for the aryl and cycloalkyl groups to be substituted with an alkyl group having from 1 to 4 carbon atoms or alternatively an alkoxy group having from 1 to 4 carbon atoms; is R2 denotes hydrogen, alkyl having from 1 to 4 carbon atoms, alkenyL having from 2 to 4 carbon atoms, a halogen atom or a benzyl radical; R3 denotes hydrogen, alkyl having from 1 to 4 carbon atoms or phenyl; and 20 R4 denotes hydrogen, alkyl having from 1 to 4 carbon atoms, alkenyl having from 2 to 4 carbon atoms, methoxymethyL or a halogen atom or a benzyl radical, as well as their cosmetically or pharraceutically acceptable salts, and at Least one antibacterial agent chosen from macroLicle antibiotics and pyranosides, as weLL as their saLts or esters.
EspeciaLLy preferred compounds of formuLa (I) are those for which Rl denotes a cycLohexyL group and R3 a Lower aLkyL group, or aLternativeLy those for which Rl denotes a Linear or branched aLkyL group and R3 a Lower aLkyL group. Among these compounds, those which are more especiaLLy preferred are 6-cycLohexyL-1-hydroxy-4-methyL- 2(lH)-pyridone, known as CicLopirox, when it is in the form of an ethanoLamine saLt, and 1-hydroxy-4-methyL-6 (2,4,4-trimethyLpentyL)-2(lH)-pyridone, known as Octopirox, when it is in the form of an ethanoLamine saLt.
EspeciaLLy preferred antibacteriaL agents are chosen from:
erythromycin derivatives, such as erythromycin, its saLts and its esters, and more especiaLLy erythro mycin estoLate, erythromycin ethyLcarbonate, erythromycin ethyLsuccinate, erythromycin gLucoheptonate, erythromycin Lactobionate, erythromycin propionate LauryL suLphate, erythromycin LinoLeate, erythromycin propionate, erythro mycin stearate, monoenic esters such as erythromycin A monooLeate; the cLinclamycin derivatives are the hydrochLoricles, paLmitates and phosphates; and the Lincomycin derivatives are the hydrochLoricles.
A preferred embodiment consists in using erythro mycin retinoates, cLinclamycin retinoates or Lincomycin retinoates as antibacterial agents. Such compounds are, in particular, described in French Patent AppLication No. 86/06,528. The compounds in question are, more especiaLLy, the retinoic esters at the 21-position of erythro- mycin A, and the retinoic esters at the 3-position of Lincomycin and of cLindamycin. The retinoic esters at the 21-position of erythromycin A may be represented by the following formula:
0 H C.. CH 3 3 H 3 C.
H OH OH .-CH3 CH RO N 3 C 11 3 ( I I H r_ CH 2 3.. 0 0 1 CH 3 CH 3 OCH3 CH 3 CH 3 00 n OR' 3 in which R denotes an all-trans-retinoyl radical or a 13-ciz-retinoyt radical and R' denotes H; the retinoyl radical having the formula:
13 11 ( I I I) (ú) (9) (9) C (E) o r is ( z) The retinoic esters at the 3-position of lincomy- cin and of ctindamycin may be represented by the following formulae:
3 CE3 N E 3 H E 11C1 C3H7 3 7 CONIL CORH CK H 0 a EL a HO H H 9 1 H 1 M R TI R 3 30 SCH3 I v) 1 ( v SC:R3 OF.
in which R has the same meaning as that given above.
These compounds may be prepared by various esterification processes, and especially an esterification carried out in an anhydrous organic solvent medium, preferably in tetrahydrofuran alone or mixed with another organic solvent such as pyridine, by reacting an excess of mixed anhydride of carbonic and aLL-trans- or 13-cisretinoic acids (prepared in situ, for example, from ethyl chLoroformate and aLL-trans- or 13-cis- acid) with ery thromycin A, Lincomycin and cLindamycin in base form, in the presence of an organic or inorganic base such as pyridine and/or sodium hydrogen carbonate.
Another esterification process consists, in particuLar for Lincomycin and cLindamycin, in using the imidazoLides of retinoic acids in an anhydrous solvent such as N,N-dimethyLformamide, in the presence of a base 8 such as sodium tert-butytate or potassium tert-butylate, leading to a mixture of retinoic esters of these antibiotics.
Other erythromycin A derivatives described, in particular, in FR-A-2,582,000, are represented by the formula (II), in which R or R' denotes a di- or trienic C18 linear acyl radical of all-cis M stereochemical configuration, and the remaining R or R denotes a hydrogen atom.
According to a preferred embodiment, R or R' denotes the following radicals:
(9Z, 12Z)-octadecadienoyl or linoleoyl (9Z, 12Z, 15Z)-octadecatrienoyl or cL-Linolenoyl, and is (6Z, 9Z, 12Z)-octadecatrienoyl or y-linolenoyl.
21-0-tinoleylerythromycin A, C-D-Linoleylerythromycin A and C-0-QLLinoLey0erythromycin A may be mentioned in particular.
These compositions can also contain other compounds, such as known sjjbstances capable of having an effect on the treatment of acne, and in particular Scarboxymethylcysteine, thiamorphotinone, S-benzyLcysteamine and their derivatives, and tioxolone.
In one embodiment, the compositions according to the invention contain keratolytic agents such as, for example, salicylic acid in proportions from 0.01 to 10% 4 i by weight, benzoyL peroxide in proportions from 0.01 to 10% by weight, resorcinoL in proportions from 0.01 to 5% by weight, retinoic acid and its derivatives, as weLL as humectants such as, for exampLe, gLycerin and urea.
In another embodiment, the compositions aLso contain steroidaL or nonsteroidaL anti-infLammatory agents such as, more especiaLLy, hydrocortisone, inclomethacin, gLycyrrhetinic acid, a-bisaboLoL, betamethasone, fLuocinoLone acetonicle and clesoxymethasone.
The pyriclone derivatives are preferabLy used in proportions from 0.01 to 5% by weight reLative to the totaL weight of the composition, and the antibacteriaL agents in proportions from 0.01 to 5% by weight reLative to the totaL weight of the composition.
Hydrocortisone or inclomethacin, when they are present, are present in proportions aCso of between 0.01 and 5% by weight reLative to the totaL weight of the of the composition.
The compositions according to the invention may be presented in various forms, such as geL, pad, cream, Lotion, spray, foam, powder, ointment, stick, cake or Liquid soap form.
The compositions can aLso contain adjuvants customariLy used in pharmaceuticaL compositions appLied on the 25 skin, and in particuLar water or mixtures of water and soLvents such as Lower aLcohoLs, for exampLe ethanoL or isopropanoL, ethyLene gLycoL, ethyLene gLycoL monomethyL, monoethyl or monobutyl ethers, propylene glycol, propylene glycol monomethyl ether and dipropylene glycol monomethyl ether, antioxidants and thickeners.
The therapeutic treatment of acne according to the invention is preferably carried out according to a process that consists in applying a sufficient quantity of the composition according to the invention two or three times per day on the areas of the skin to be treated, continuing this for a period of 6 to 30 weeks, and prefer- ably 12 to 24 weeks.
The compositions according to the invention can be used preventively, in particular on the areas of skin likely to be affected by acne.
The compositions according to the invention may also be used for the cosmetic treatment of the skin; in particular, they enable comedones to be treated and facilitate extrusion of the latter, and hence cleanse the skin.
The Applicant found that the compositions according to the invention not only enabled a very rapid improve- ment to be obtained in the inflammatory state of acne, but also enabled a decrease to be brought about in the lesions of the so-called first type, the feature of which is that they are non-inflammatory.
The examples which follow are designed to illus- trate the invention, no limitation of the latter being implied.
z - 11 PREPARATION EXAMPLE 1 Preparation of 21-0-(13-cis-retinoyl)erythromycin A 9 (16.6 mmol) of 13-cis-retinoic acid are dis- solved in 35 ml of anhydrous tetrahydrofuran in a round s bottomed flask and under an inert atmosphere; the reaction mixture is cooled to OOC and then 3 mI (38 mmol) of anhydrous pyridine and 1.6 ml (16.6 mmol) of ethyl chloro formate are poured in. The solution is stirred for 5 minutes and 2.5 9 (30 mmol) of sodium hydrogen carbonate are added, followed by 4.9 9 (6.7 mmol) of erythromycin A, previously dissolved in 150 mt of tetrahydrofuran. The reaction inixture is then left with stirring for 10 hours while being allowed to return to room temperature (thin layer chromatography on silica gel: methylene chloride/ methanol, 10%). The solution is poured into 60 mI of water and then extracted with ethyl acetate. The organic phase is dried over magnesium sulphate, filtered and then concentrated under partial vacuum. The crude product thereby obtained is chromatographed on a column of silica gel (HPLC) using the etuant ethyl acetatelhexane (7:3), Leading to the isolation of 4.4 g (65% yield) of pure 21-0-(13-cis- retinoyl)erythromycin A. M.p. 820C (hexanelethyl acetate) [cc] 22 = -170 (C = 6 mg/mI, dichloromethane) D Microanalysis: C57H93NO14 c 67.36 Calculated % M = 1016.4 H N 9.22 1.38 Found %:
67.48 9.32 1.38 Infrared: band at 1735 cm-1 (ester) 13C NMR (CDC13. internal ref. TMS) Negative y effects at the 11-position (-2.2 ppm) and 31-position (-2.1 ppm), indicate the 21-position of the ester. Carbons C20 (20.94 ppm), C"14 (117.28 ppm) and C12 (131.9 ppm) of the retinoic chain are in agree ment with the 13-cis stereochemistry of the retinoic chain.
PREPARATION EXAMPLE 2 is Preparation of 21-0-(all-trans-retinoyl)erythromycin A 9 (16.6 mmol) of all-trans-retinoic acid are dissolved in 35 mI of anhydrous tetrahydrofuran in a roundbottomed flask and under an inert atmosphere, the reaction mixture is cooled to OOC and then 3 mI (38 mmol) of anhydrous pyridine and 1.6 ml (16.6 mmol) of ethyl chloroformate are poured in; the solution is stirred for 5 minutes and 2.5 9 (30 mmol) of sodium hydrogen carbonate are added, followed by 4.9 g (6.7 inmol) of erythromycin A, previously dissolved in 150 ot of tetrahydrofuran. The reaction mixture is then left with stirring for 10 hours while being allowed to return to room temperature (thin layer chromatography on silica get: methylene chloride/ methanol, 1OV. The solution is poured into 60 mI of water and then extracted with ethyl acetate. The organic phase is dried over magnesium sulphate, filtered and then concentrated under partial vacuum. The crude product 1 thereby obtained.is chromatographed on a column of sili gel (HPLC) using the eluant ethyl acetatelhexane (7:3), leading to the isolation of 4.1 9 (60% yield) of pure 21-0-(all-trans-retinoyt)erythromycin A.
[C1122 = -650 (C = 2 mglmt, dichloromethane) D Microanalysis C57H93NO14.4H20; M = 1088.5 C H N Calculated % 62.89 9.35 Found %: 62.91 8.90 13 C NMR (CDC13,, internal ref. TMS) Negative y effects at the V-position (-2 ppm) and 31-position (-1.9 ppm), indicate the 2'-position of the ester. Carbons C"20 (14.1 ppm), C"14 (119. 36 ppm) and C"12 (135.19 ppm) are in agreement with the all- is trans stereochemistry of the retinoic chain. PREPARATION EXAMPLE 3 Preparation of 3-0-(all-trans-retinoyl)ctindamycin 9 (16.6 mmol) of all-trans-retinoic acid are dissolved in 30 mI of anhydrous tetrahydrofuran in a round-bottomed flask and under an inert atmosphere; the reaction mixture is cooled to OOC and then 6 ml (76 mmol) of anhydrous pyridine and 1.6 ml (16.6 mmol) of ethyl chloroformate are poured in; the solution is stirred for 5 minutes and 1.25 9 (15 mmol) of sodium hydrogen carbonate are added, followed by 2.35 9 (5.5 mmol) of clindamycin, previously dissolved in 100 ml of a tetra hydrofuran/pyridine M2) mixture. The reaction mixture 1.29 1.29 14 - 1 5 is is then left with stirring for 10 hours while being allowed to return to room temperature (thin layer chromatography on silica gel: methylene chloridelmethanol 5%). The solution is poured into 80 ml of water and then extracted with ethyl acetate. The organic phase is dried over magnesium sulphate, filtered and then concentrated under partial vacuum. The crude product thereby obtained is chromatographed on a column of silica gel (HPLC) using the eluent ethyl acetatelhexane (5:5), leading to the isolation of 2.15 g (55% yield) of pure 3-0-(alltransretinoyOclindamycin. M.p. 620C [cc] 22 = +500 (C = 100 mglml, dichloromethane) D Microanalysis: C38H59N2SO6C1.2.5H20; M = 752.5 C H N Calculated %:
Found %:
13 60.44 8.08 3.23 60.66 8.57 3.72 C NMR (CDC13. internal ref. TMS): negative effects at the 4-position (-2.8 ppm) and 2-position (-1.9 ppm). The chemical shifts of C"14 (117.84 ppm) and C"20 (14.11 ppm) confirm the all-trans stereochemistry of the retinoyl chain.
PREPARATION EXAMPLE 4 Preparation of 3-0-(13-cis-retinoyl)cli_ndamyein g (16.6 mmol) of 13-cis-retinoic acid are dissolved in 30 ml of anhydrous tetrahydrofuran in a roundbottomed flask and under an inert atmosphere; the reaction 1 Q 1 mixture is cooled to OOC and then 6 ml (76 mmol) of anhydrous pyridine and 1.6 mI (16.6 mmol) of ethyl chloroformate are poured in; the solution is stirred for 5 minutes and 1.25 g (15 mmol) of sodium hydrogen carbonate are added, followed by 2.35 g (5.5 mmol) of clindamycin, previously dissolved in 100 ml of a tetrahydrofuranIpyridine (M) mixture. The reaction mixture is then left with stirring for 10 hours while being allowed to return to room temperature (thin layer chromatography on silica gel; methylene chloridelmethanol 5%). The solution is poured into 80 mI of water and then extracted with ethyl acetate. The organic phase is dried over magnesium sulphate, filtered and then concentrated under partial vacuum. The crude product thereby obtained is chromatographed on a column of silica gel (HPLC) using the eluant ethyl acetate/hexane (5..5), leading to the isolation of 2 9 (51% yield) of pure 3-0-(13-cis-retinoyl)clindawycin. M.p. 950C (hexanelethyl acetate) [C1320 = +1110 (C = 15 inglml, dichtoromethane) D Microanalysis C38H59CIN2S06; M = 707.4 C H Calculated % 64.52 8.41 Found %: 64.47 8.45 13 C NMR (CDC13,, internal ref. TMS) The position of the ester is indicated by the positive B effect at the 3- position (+1.77 ppm) and the k - 16 negative y effects at the 2-position (-1.4 ppm) and 4-position (-2.5 ppm). The 13-cis configuration is con firmed by C20 (20.93 ppm) and C"14 (115.94 ppm).
PREPARATION EXAMPLE 5 Preparation of 3-0-(13-cis-retinoyl)tincomycin 9 (16.6 mmol) of 13-cis-retinoic acid are dis solved in 30 mt of anhydrous tetrahydrofuran in a round bottomed flask under an inert atmosphere; the reaction mixture is cooled to OOC and then 6 mt (76 mmol) of anhydrous pyridine and 1.6 mI (16.6 mmol) of ethyl chloroformate are poured in; the solution is stirred for 5 minutes and 1.25 9 (15 mmol) of sodium hydrogen carbonate are added, followed by 2.2 9 (5.4 mmol) of lincomycin, previously dissolved in 100 mI of a tetrahydrofuranIpyridin (7:3) mixture. The reaction mixture is then left with stirring for 10 hours while being allowed to return to room temperature (thin layer chromatography on silica gel: methylene chloridelmethanol, 10%). The solution is poured into 100 ml of water and then extracted with ethyl acetate. The organic phase is dried over magnesium sulphate, filtered and then concentrated under partial vacuum. The crude product thereby obtained is chromatographed on a column of silica gel (HPLC) using the eluant ethyl acetatelhexane (8:2), leading to the isolation of 1.85 g (50% yield) of pure 3-0-(13-cis-retinoyl)lincomycin. M.p. 950 (hexanelethyl acetate) ECL120 = +1030 (C = 7 mgImI, dichloromethane) D Microanalysis c38H6ON2S07-2-SH20; M = 734.5 c H Calculated % 62.18 9.03 Found %: 62.33 8.64 13C NMR (CDC13.. internal ref. TMS) The position of the ester is indicated by the positive $ effect at the 3- position (+1.6 ppm) and the negative y effects at the 2-position (-2.4 ppm) and 4-position (-1.9 PPm). The 13-cis configuration is con- firmed by C20 (20.98 ppm) and C14 (115.83 ppm).
PREPARATION EXAMPLE 6 Preparation of a mixture of 7-0-(all-trans-retinoyl)lin:
comycin, 3-0-(all-trans-retinoyl)lincomycin and 2-0-(atl-trans-retinoyt)lincomycin monoesters 9 (74 mmol) of Lincomycin are dissolved in 300 ml of anhydrous N,N-dimethylformamide in a round bottomed fLask and under an inert atmosphere, 830 mg (7.4 amol) of potassium tert-butylate are then added and stirring is continued at room temperature for 90 minutes.
A solution of 13 9 (37 mool) of 1-(all-trans-retinoyl)imi dazote in 150 mL of N,N-dimethylformamide is then poured in and the resulting mixture is stirred at room temperat ure for 12 hours (thin layer chromatography on silica gel: methylene chloridelmethanol, 7.5%). The solution is poured into 500 mt of water and then extracted with ethyl acetate. The organic phase is dried over magnesium sulphate, filtered and then concentrated under partial vacuum.
The crude product thereby obtained is chromatographed on a column of silica gel (HPLC) using the eluant ethyl acetate/hexane (7:3), leading to the isolation of 39 g (77%) of a mixture of all-trans-retinoic monoesters of 5 Lincomycin at the 2-, 3- and 7-positions. 13C NMR (CDC13.. internal ref. TMS) - Negative y effects at the 8-position (-2.5 ppm) and the 6position (-3.8 ppm) indicate the site of esterification of a monoester at the 7-position, - Negative y effect at the 1-position (-4 ppm) indicates the monoester at the 2-position, and negative y effects at the 2-position (-2 ppm) and 4-position (-2.6 ppm) indicate the position of the monoester at the 3-position. The positions of Cl are at 85.06 ppm for the 2monoester, is at-88.45 ppm for the 7-monoester and at 89.67 ppm for the monoester at the 3-position. The all-trans configuration of the retinoic chain is indicated for C14 at 117.78 ppm and for C20 at 14.08 ppm; a trace of isomerization is noted by the pres20 ence of a peak at 115.2 ppm W'14) indicating the 13-cis isomer.
PREPARATION EXAMPLE 7 Preparation of a mixture of 2-0-(all-transretinoyl)clindamycin, 3-0-(all-trans-retinoyl)clindamycin and 4-0-(alltrans-retinoyl)clindamycin monoesters 20 9 (47 mmol) of clindamycin are dissolved in 250 ml of an anhydrous N,N-dimethytformamide in a round- It 19 bottomed flask and under an inert atmosphere, and 527 mg (4.7 mmol) of potassium tert-butylate are then added to the reaction medium, which is then stirred at room temperature for 90 minutes. A solution of 8.250 9 (23.5 mmot) of 1-(all-trans-retinoyl)imidazole in 150 mt of anhydrous N.Ndimethytformamide is then poured in and the resulting medium is stirred at room temperature for 12 hours (thin Layer chromatography on silica gel: methylene chloride/ methanol, 5%). The solution is then poured into 500 ml of water, after which it is extracted with ethyl acetate. The organic phase is dried over magnesium sulphate, fittered and then concentrated under partial vacuum. The crude product thereby obtained is chromatographed on a column of silica get (HPLC) using the eluant ethyl acetate/ hexane (5:5), Leading to the isolation of 28 g (85%) of a mixture of all-trans-retinoic monoesters of clindamycin at the 2-, 3- and 4-positions. 13 C NMR (C0C13. internal ref. TMS) ' - Negative y effect at the 1-position (-3 ppm) indicates the 2-position of the ester, - Negative y effects at the 4-position (-2.8 ppm) and 2-position (-1.9 ppm) indicate the monoester at the 3 posi tion, and weak negative y effect at the 3-position indicates the monoester at the 4-position.
The positions of Cl are at 84.63 ppm for the 2-monoester, at 88.79 ppm for the 3-monoester and at 87.98 ppm for the 4-monoester.
The all-trans configuration of the retinoic chain is predominant (C"14 at 117.5 ppm and C20 at 14.08 ppm), but there are clear traces of isomerization, in particular at C20 and C14.
EXAMPLE 1 ANTI-ACNE LOTION The following composition is prepared:
Erythromycin Octopirox Butylated hydroxytoluene (SHT)Ibutylated hydroxyanisole (SHA) antioxidant Water/isopropanol solution (60:40 by volume) qs EXAMPLE 2
ANTI-ACNE LOTION The following composition is prepared:
Clindamycin Octopirox Senzoyl peroxide Antioxidant (SHT, SHA) Waterlethanot solution (60:40 by volume) h c 2 9 1 9 0.4 9 9 0.6 9 0.02 g 2.5 g 0.1 g 9 l, - 21 EXAMPLE 3 ANTI-ACNE GEL The foLLowing composition is prepared: Erythromycin SaLicyLic acid Octopirox PoLyacryLic acid crossLinked with a poLyfunctionaL agent, soLd by the company S.F. GOODRICH under the trade name "CARBOPOL 941" Antioxiclant (BHT, BHA) EthanoL Water EXAMPLE 4 q s GEL The foLLowing composition is prepared:
Erythromycin LinoLeate CycLopirox HydroxypropyL ceLLuLose soLd by the company HERCULES under the trade name "KLUCEL H" Antioxiclant (BHT, BHA) EthanoL Water qs 2 9 0.5 g 2 9 0.5 g 0.5 9 9 9 3 9 1 9 1 9 0.1 g 9 9

Claims (21)

1. A composition suitable for topical application which comprises, in a physiologically acceptable medium, at least one pyridone derivative corresponding to the formula:
R1 R2 3 in which:
(I) R, denotes hydrogen, linear or branched alkyl having from 1 to 17 carbon atoms, cycloalkyl having from 5 to 8 carbon atoms, cycloalkylalkylene, in which the alkylene group has from 1 to 4 carbon atoms, aryl, aralkyl in which the alkyl group has from 1 to 4 carbon atoms, arylalkenyl in which the alkenyl group has from 2 to 4 carbon atoms, such that the aryl and cycloalkyl groups can be substituted by an alkyl or alkoxy group having from 1 to 4 carbon atoms; R 2 denotes hydrogen, alkyl having from 1 to 4 carbon atoms, alkenyl having from 2 to 4 carbon atoms, halogen or benzyl; R 3 denotes hydrogen, alkyl having from 1 to 4 carbon atoms or phenyl; and R., denotes hydrogen, alkyl having from 1 to 4 carbon atoms, alkenyl having from 2 to 4 carbon atoms, methoxymethyl halogen, or a benzyl radical; or a cosmetically or pharmaceutically acceptable salt thereof, and at least one 7 antibacterial agent which is a macrolide antibiotic or pyranoside, or a salt or ester thereof.
2. A composition according to claim 1, in which R, denotes a cyclohexyl or linear or branched alkyl group and R 3 denotes a lower alkyl group, for example of 1 to 6 carbon atoms.
3. A composition according to claim 1 or 2, in which the compound of formula (I) is 6-cyclohexyl-1-hydroxy4-methyl-2(1H)-pyridone or 1-hydroxy4-methyl-6-(2,4,4- trimethylpentyl)-2(1H)-pyridone.
4. A composition according to any one of claims 1 to 3, in which the antibacterial agent is an erythromycin, clindamycin or lincomycin derivative.
5. A composition according to claim 4, in which the erythromycin derivative is erythromycin or an estolate, ethylcarbonate, ethylsuccinate, glucoheptonate, lactobionate, propionate lauryl sulphate, propionate, stearate, linoleate or monoenic, di- or trienic ester of erythromycin.
6. A composition according to claim 4, in which the clindamycin derivative is a hydrochloride, palmitate or phosphate, and the lincomycin derivative is lincomycin hydrochloride.
7. A composition according to any one of claims 1 to 6, in which the antibacterial agent is an erythromycin retinoate, clindamycin retinoate or lincomycin retinoate.
8. A composition according to any one of claims 1 to 7 which also contains a keratolytic agent.
9. A composition according to claim 8, in which the keratolytic agent is benzoyl peroxide, salicylic acid or resorcinol.
10. A composition according to any one of claims 1 to 9 which also contains S-carboxymethyl-cysteine, thiamorpholinone, S-benzylcysteamine or a derivative thereof or tioxolone.
11. A composition according to any one of claims 1 to 10 which also contains at least one steroidal or nonsteroidal anti- inflammatory agent.
12. A composition according to claim 11, in which the anti-inflammatory agent is hydrocortisone, indomethacin, glycyrrhetinic acid, m-bisabolol, betamethasone, fluocinolone acetonide or desoxymethasone.
13. A composition according to any one of claims 1 to 12, in which the compound of formula (I) is present in an amount from 0.01 to 5% by weight, and in that the antibacterial agent is present in an amount from 0.01 to 5% by weight, relative to the total weight of the composition.
14. A composition according to any one of claims 1 to 13 which is in the form of a gel, pad, cream, lotion, spray, ointment or stick. 25
15. A composition according to any one of claims 1 to 14 which contains water or a mixture of water and a 1 - lower alcohol, glycol or glycol ether.
16. A composition according to any one of claims 1 to 15 which also contains one or more thickening agents, antioxidants, colouring agents or perfumes.
17. A composition according to any one of claims 1 to 16, formulated for use in the therapeutic treatment of acne.
18. A composition according to any one of claims 1 to 16, formulated for use in the cosmetic treatment of the 10 skin.
19. A composition according to claim 1 substantially as described in any one of Examples 1 to 4.
20. Use of the composition as defined in any one of claims 1 to 19, for the preparation of a medicinal product 15 intended for treating acne.
21. Process for cosmetic treatment which comprises applying to the area to be treated a composition as defined in any one of claims 1 to 19.
1 Published 1988 at The Paten-. Off-.e. State Ho:sc. 66 71 HiC'.'Ho.
bcrr.. London WCIR 4TF Purther cc;,c- may be obtained frc;r,, Tr.e Patent Officc Sales Branch. St Ma-3, Cray. Orpingtcr.. Kent BR5 3RD. Printed by Multiplex techniques ltd, S-, Ma:T Cray. Kent. Con. 1187
GB8816916A 1987-07-17 1988-07-15 Pharmaceutical and cosmetic compositions based on pyridones and on antibacterial agents Expired - Lifetime GB2208149B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
LU86945A LU86945A1 (en) 1987-07-17 1987-07-17 PHARMACEUTICAL AND COSMETIC COMPOSITIONS BASED ON PYRIDONES AND ANTIBACTERIAL AGENTS

Publications (3)

Publication Number Publication Date
GB8816916D0 GB8816916D0 (en) 1988-08-17
GB2208149A true GB2208149A (en) 1989-03-08
GB2208149B GB2208149B (en) 1991-10-09

Family

ID=19730948

Family Applications (1)

Application Number Title Priority Date Filing Date
GB8816916A Expired - Lifetime GB2208149B (en) 1987-07-17 1988-07-15 Pharmaceutical and cosmetic compositions based on pyridones and on antibacterial agents

Country Status (6)

Country Link
BE (1) BE1002690A4 (en)
CH (1) CH674930A5 (en)
FR (1) FR2618072B1 (en)
GB (1) GB2208149B (en)
IT (1) IT1223695B (en)
LU (1) LU86945A1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4906454A (en) * 1989-02-23 1990-03-06 The Procter & Gamble Company Deodorant compositions containing specific piroctone salts and perfumes
US5487884A (en) * 1987-10-22 1996-01-30 The Procter & Gamble Company Photoprotection compositions comprising chelating agents
WO1998013042A1 (en) * 1996-09-27 1998-04-02 Hoechst Aktiengesellschaft Antimycotic gel with high active substance release
WO1998013043A1 (en) * 1996-09-27 1998-04-02 Hoechst Aktiengesellschaft Use of 1-hydroxy-2-pyridones for the treatment of skin diseases
EP0909174A1 (en) * 1996-03-26 1999-04-21 The Regents Of The University Of California TREATMENT OF CYSTIC DISEASE WITH TNF-$g(a)
US6455551B1 (en) 1996-10-30 2002-09-24 Aventis Pharma Deutschland Gmbh Use of 1-hydroxy-2-pyridones for treating mucosa diseases which are difficult to treat
US7981909B2 (en) 1996-09-27 2011-07-19 Medicis Pharmaceutical Corporation Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3830509A1 (en) * 1988-09-08 1990-03-22 Hoechst Ag MEDICINAL PRODUCTS WITH SYNERGISTIC ANTIMYCOTIC AND ANTIVIRAL EFFECTIVENESS
FR2685638A1 (en) * 1991-12-31 1993-07-02 Biorga Sa Laboratoires Compositions for cosmetic and/or dermatological use, comprising a combination of pyrithione zinc, piroctone olamine and a derivative of collagen and of fatty acid
FR2722689B1 (en) * 1994-07-20 1996-10-04 Fabre Pierre Dermo Cosmetique NOVEL COMBINATION PRODUCT COMPRISING AN ANTIFUNGAL AGENT AND CROTAMITON AS A POTENTIALIZER OF THE ACTIVITY OF THE ANTIFUNGAL AGENT, AND DERMATOLOGICAL AND / OR COSMETIC COMPOSITIONS COMPRISING THE SAME
DE19917548A1 (en) * 1999-04-19 2000-10-26 August Wolff Gmbh & Co Arzneim Stable topical pharmaceutical composition for treating skin diseases, especially acne, contains erythromycin higher fatty acid salt in liquid or viscous carrier
ITMI20061770A1 (en) * 2006-09-18 2008-03-19 Carlo Ghisalberti COSMETIC METHOD OF REDUCING EYES

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2448903A1 (en) * 1979-02-19 1980-09-12 Martin Henri Fast acting antimicrobial compsns. - contg. antimicrobial, enzyme, antiinflammatory, and opt. local anaesthetic, keratolytic, mucolytic and emulsifier
US4299826A (en) * 1979-10-12 1981-11-10 The Procter & Gamble Company Anti-acne composition
DE3140954A1 (en) * 1981-10-15 1983-05-05 Hoechst Ag Use of 1-hydroxy-2-pyridones for the prophylaxis and treatment of acne
GB8524508D0 (en) * 1985-10-04 1985-11-06 Beecham Group Plc Composition

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5487884A (en) * 1987-10-22 1996-01-30 The Procter & Gamble Company Photoprotection compositions comprising chelating agents
US4906454A (en) * 1989-02-23 1990-03-06 The Procter & Gamble Company Deodorant compositions containing specific piroctone salts and perfumes
EP0909174A1 (en) * 1996-03-26 1999-04-21 The Regents Of The University Of California TREATMENT OF CYSTIC DISEASE WITH TNF-$g(a)
EP0909174A4 (en) * 1996-03-26 2003-01-22 Univ California Treatment of cystic disease with tnf-alpha
WO1998013042A1 (en) * 1996-09-27 1998-04-02 Hoechst Aktiengesellschaft Antimycotic gel with high active substance release
WO1998013043A1 (en) * 1996-09-27 1998-04-02 Hoechst Aktiengesellschaft Use of 1-hydroxy-2-pyridones for the treatment of skin diseases
JP2001501609A (en) * 1996-09-27 2001-02-06 ヘキスト・アクチエンゲゼルシヤフト Antifungal gel with high active compound release
US6469033B1 (en) 1996-09-27 2002-10-22 Aventis Pharma Deutschland Gmbh Use of 1-hydroxy-2-pyridones for the treatment of skin diseases
US7018656B2 (en) 1996-09-27 2006-03-28 Aventis Pharma Deutschland Gmbh Antimycotic gel with high active substance release
US7026337B2 (en) 1996-09-27 2006-04-11 Aventis Pharma Deutschland Gmbh Antimycotic gel having high active compound release
US7981909B2 (en) 1996-09-27 2011-07-19 Medicis Pharmaceutical Corporation Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis
US6455551B1 (en) 1996-10-30 2002-09-24 Aventis Pharma Deutschland Gmbh Use of 1-hydroxy-2-pyridones for treating mucosa diseases which are difficult to treat

Also Published As

Publication number Publication date
BE1002690A4 (en) 1991-05-07
IT1223695B (en) 1990-09-29
GB8816916D0 (en) 1988-08-17
IT8867667A0 (en) 1988-07-15
LU86945A1 (en) 1989-03-08
FR2618072A1 (en) 1989-01-20
GB2208149B (en) 1991-10-09
CH674930A5 (en) 1990-08-15
FR2618072B1 (en) 1993-10-15

Similar Documents

Publication Publication Date Title
US5045533A (en) Retinoic esters of antibiotics and pharmaceutical and cosmetic compositions containing them
US4668664A (en) Bi- or tri-enic fatty esters of erythromycin A; pharmaceutical and cosmetic compositions containing them
GB2208149A (en) Pharmaceutical and cosmetic compositions based on pyridones and antibacterial agents
US5004730A (en) Polycyclic aromatic esters of macrolidic and lincosamidic antibiotics and pharmaceutical and cosmetic compositions containing them
DK169345B1 (en) Retinoic acid esters of erythromycin A, their preparation and pharmaceutical and cosmetic preparations thereof
BE1001203A3 (en) COMPOSITION BASED ON DERIVATIVES hydroxypyridone TO REDUCE HAIR LOSS.
US5158773A (en) Retinoid esters
KR840000678B1 (en) Method of preparing for sugar derivatives
US5116960A (en) Amphotericin b derivatives
US5004732A (en) Polyaromatic esters of macrolidic and lincosamidic antibiotics and pharmaceutical and cosmetic compositions containing them
NO823717L (en) PROCEDURE FOR THE PREPARATION OF NITROIMIDAZOLD DERIVATIVES
US5004731A (en) Unsaturated cycloaliphatic esters of macrolidic and lincosamidic antibiotics and pharmaceutical and cosmetic compositions containing them
JP3014401B2 (en) Retinoic acid ester of D-desosamine, its preparation, human or veterinary medicine and cosmetic composition
US5004733A (en) Esters of the etretinic type or related to macrolidic and lincosamidic antibiotics and pharmaceutical and cosmetic compositions containing said esters
US4130665A (en) A-norandrostane derivatives
NO168647B (en) ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE RETINIC ACID ESTERS OF LINCOMYCIN AND CLINDAMYCIN.
JPH01193289A (en) Diaromatic ester of macrolide and lincosamide antibiotics, production thereof and drug/cosmetics
FI69471C (en) FOERFARANDE FOER FRAMSTAELLNING AV NYA THERAPEUTIC EQUIPMENT
DE19603510A1 (en) Use of new and known terrecyclolic acid compounds (tri:cyclo:undecane(s))
JPH01193291A (en) Aromatic ester of macrolide and lincosamide antibiotics, production thereof and drug/cosmetics

Legal Events

Date Code Title Description
PE20 Patent expired after termination of 20 years

Expiry date: 20080714